Bumper payout for managers as Glaxo agrees $13.1bn Novartis deal

clock

GlaxoSmithKline, the UK's largest pharmaceutical group, has agreed to sell one of its businesses to rival Novartis, in a deal which will see it return billions of pounds to shareholders.

The group - a favourite holding of many income funds in the UK - announced on Tuesday it had sold its oncology unit to Swiss rival Novartis for an initial sum of $14.5bn (£8.63bn). In a multi-faceted agreement, Glaxo will also buy Novartis' vaccines business for $7.1bn, while the pair will embark on a joint venture in the consumer healthcare market where both already have a strong presence. The deal - which should complete in the first half of next year - will boost Glaxo's earnings per share, it said, while it will also provide a bumper payout to shareholders. Glaxo said £4bn woul...

To continue reading this article...

Join Professional Adviser for free

  • Unlimited access to real-time news, industry insights and market intelligence
  • Stay ahead of the curve with spotlights on emerging trends and technologies
  • Receive breaking news stories straight to your inbox in the daily newsletters
  • Make smart business decisions with the latest developments in regulation, investing retirement and protection
  • Members-only access to the editor’s weekly Friday commentary
  • Be the first to hear about our events and awards programmes

Join

 

Already a Professional Adviser member?

Login

More on Equities

Investment, Talks Webinar: Changing global patterns can bring new opportunities

Investment, Talks Webinar: Changing global patterns can bring new opportunities

Join Investment Week and Capital Group on the 22nd May at 11am

Hardeep Tawakley
clock 08 May 2025 • 1 min read
Webinar: What's next for equities?

Webinar: What's next for equities?

How can investors navigate the impact of tariffs and a rapidly changing global economy?

Investment Week
clock 08 May 2025 • 1 min read
Will a tech shake-up stop the rise of passives?

Will a tech shake-up stop the rise of passives?

'That kind of built-in safety net is hard to beat'

Laura Suter
clock 18 February 2025 • 2 min read